WungkiParkMD

PubMed

• Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.
  Alex B Blair, Shannon N Radomski, Joanne Chou, Mengyuan Liu, Thomas Clark Howell
  Annals of Surgical Oncology. 2025-03-01
• Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort.
  Fergus Keane, Catherine O'Connor, Drew Moss, Joanne F Chou, Maria A Perry
  Journal of the National Cancer Institute. 2025-03-01
• 1 citations
  RNA neoantigen vaccines prime long-lived CD8T cells in pancreatic cancer.
  Zachary Sethna, Pablo Guasp, Charlotte Reiche, Martina Milighetti, Nicholas Ceglia
  Nature. 2025-03-01

Abstracts/Posters

• Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant Abstract
  Wungki Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• An Inflammation Paradox: Obesity and Neutrophil-Lymphocyte Ratio in Immunotherapy.
  Park W, Florou V, Torres A, Saravia D, Algaze S, and Lopes G, AACR Annual Meeting, Chicago, IL, 1/1/2018
• High Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) and its Reactive Increase as Better Predictors of for Poor Clinical Outcomes Compared To Tumor Mutation Burden (...
  Florou V, Park W, Torres A, Algaze S, Saravia D, Kwon D, Hosein P, Merchan J, Wilky B, Lockhart C, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Predicting outcomes of patients with advanced non-small cell lung cancer treated with PD-1/PDL-1 inhibitors: independent international validation of the iSEND model.
  Park W, Mezquita L, Okabe N, Kwon D, Saravia D, Chae Y, Desai A, Planchard D, Caramella C, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Neutrophil-Lymphocyte-Ratio complements the prediction ability of PD-L1 expression in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibit...
  Saravia D, Okabe N, Park W, Kwon D, Mezquita L, Chae Y, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• A Phase II Trial of Axitinib Plus Pembrolizumab for Patients with Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS).
  Wilky B, Trucco M, Kolonias D, Wieder E, Subhawong T, Rosenberg A, Kwon D, Park W, Florou V, Kerr D, Sfakianaki E, Merchan J, Komanduri K, Trent J, ASCO Annual Meeting, Chicago, IL, 1/1/2018
• Oncolytic virotherapy is an effective immunotherapy: meta-analysis for clinical trials.
  Park W, Algaze S, Abi Aad S, Elias R, Kwon D, Chavez V, Jing Y, Acquavella N, Merchan J, ASCO Annual meeting, Chicago, IL, 1/1/2017
• Outcomes of biliary stents in advanced pancreatic cancer in the era of FOLFIRINOX therapy.
  Park W, Mankal P, O’Reilly E, ASCO Annual meeting, Chicago, IL, 1/1/2017
• Neutrophil-Rich Inflammation and PD1/PD-L1 inhibitor Resistance in Advanced Non-Small Cell Lung Cancer Patients.
  Park W, Algaze S, Florou V, Saravia D, Kwon D, and Lopes G, SITC Annual Meeting, Washington, DC, 1/1/2017
• iSEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors.
  Park W, Kwon D, Desai A, Florou V, Saravia D, Warsch J, Chae Y, Ishkanian A, Jahanzeb M, Mudad R, and Lopes G, WCLC Annual Meeting, Yokohama, Japan, 1/1/2017
• Correlating iSEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients on Nivolumab
  Park W, Lopes G, Kwon D, Florou V, Saravia D, Chae Y, Warsch J, Ishkanian A, Jahanzeb M, and Mudad R, WCLC Annual Meeting, Yokohama, Japan, 1/1/2017
• Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.
  Park W, Vallabhaneni G, Martin L, Adsay V, Staley C, Maithel S, Wang Z, Chen Z, El-Rayes B, Bekaii-Saab T, ASCO Annual Meeting, IL, 1/1/2012
• A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer.
  Park W, Pantazides B, El-Rayes B, Shelton J, Yu D, Landry J, International Journal of Radiation Oncology, IL, 1/1/2012
• Join now to see all

Lectures

• Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: Independent international validation of the iSEND model. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• ASCO Review – Updates & Advances in Cancer Therapy 
  Ft. Lauderdale, FL - 1/1/2017
• The Basics of Lung Cancer 
  Miami, FL - 1/1/2017
• Join now to see all